ArticleMetabolic brain disease2025
Piracetam attenuates oxidative stress and inflammation-induced neuronal cell death in rats with vascular dementia potentially via the activation of the AMPK/SIRT-1/Nrf-2 signaling pathway.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neuroprotective effects of piracetam in vascular dementia: a review of toll-like receptor 4 -mediated neuroinflammatory pathways.Inflammopharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Chronic cerebral hypoperfusion (CCH) is the second leading cause of dementia and a major contributor to vascular dementia (VaD). Among the mechanisms underlying CCH-induced cognitive decline, programmed cell death plays a pivotal role. Lytic forms of programmed cell death, including necroptosis and pyroptosis, have recently been identified as consequences of chronic inflammation. However, their precise involvement in VaD remains unclear. It has been demonstrated that piracetam has neuroprotective and cognitive-enhancing properties, potentially through anti-inflammatory and antioxidant mechanisms. Nevertheless, its effects in the context of VaD have not yet been fully investigated. This study aimed to investigate the therapeutic potential of piracetam and elucidate any underlying mechanisms. Male Wistar rats underwent bilateral common carotid artery occlusion to induce CCH. Following this procedure, the rats received either piracetam (600 mg/kg) or resveratrol (20 mg/kg) daily for 28 days. Before euthanasia, cognitive performance was assessed using the Morris water maze test. Then biochemical analyses, including Western blotting and immunohistochemistry, were performed to assess markers of oxidative stress, neuroinflammation, pyroptosis, and necroptosis. Our findings demonstrated that piracetam reduced oxidative stress, suppressed neuroinflammatory responses, enhanced superoxide dismutase activity, and provided protection against pyroptotic and necroptotic cell death. Mechanistic studies showed that piracetam activated AMP-activated protein kinase (AMPK), which in turn upregulated sirtuin 1 (SIRT-1) and nuclear factor erythroid 2-related factor 2 (Nrf-2), leading to improved cognitive performance. In conclusion, piracetam ameliorates cognitive impairment in CCH-induced VaD by modulating oxidative damage, neuroinflammation, and inflammatory cell death, potentially through activation of the AMPK/SIRT-1/Nrf-2 signaling pathway.
Indexed as
Identifiers
41251844What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.